{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-025240","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.217538+00:00","generated_at":"2026-05-15T18:05:33.481277+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Abbott completes $20B senior notes offering to fund Exact Sciences acquisition","bullets":["Issued $20B in eight tranches: Floating Rate Notes due 2029, fixed-rate notes from 3.700% to 5.600% with maturities 2029–2066.","Net proceeds to fund Exact Sciences acquisition (announced Nov 2025), repay Exact Sciences debt, pay fees, and general purposes.","If Exact Sciences acquisition not consummated by Feb 17, 2027, Abbott must redeem notes at 101% plus accrued interest.","Underwriters include Morgan Stanley, Barclays, BofA Securities, J.P. Morgan."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-025240","json":"https://secwatch.observer/filing/0001104659-26-025240.json","markdown":"https://secwatch.observer/filing/0001104659-26-025240.md","text":"https://secwatch.observer/filing/0001104659-26-025240.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000110465926025240/0001104659-26-025240-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000110465926025240/tm264905d8_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:05:33.481277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52fc7ee8ff3d92cccaa0892323e1b42f40af9c61","claim":"ABBOTT LABORATORIES incurred senior notes of $20,000,000,000 aggregate principal amount with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC at Floating Rate Notes due 2029, 3.700% Notes due 2029, 4.000% Notes due 2031, 4.30 maturing 2029, 2029, 2031, 2033, 2036, 2038, 2056 and 2066.","evidence_excerpt":"On March 9, 2026, Abbott Laboratories (“Abbott”) completed the public offering and issuance of $20,000,000,000 aggregate principal amount of senior notes","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1800/000110465926025240/0001104659-26-025240-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"$20,000,000,000 aggregate principal amount"},{"label":"Counterparty","value":"Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC"},{"label":"Rate","value":"Floating Rate Notes due 2029, 3.700% Notes due 2029, 4.000% Notes due 2031, 4.30"},{"label":"Maturity","value":"2029, 2029, 2031, 2033, 2036, 2038, 2056 and 2066"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"ff7d9f4f68de024e8ac32e689b1d43bf1d451776","claim":"ABBOTT LABORATORIES entered into Pricing Agreement with Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC valued at $20,000,000,000 aggregate principal amount (effective 2026-02-23).","evidence_excerpt":"The Notes were sold pursuant to a pricing agreement, dated February 23, 2026 (the “Pricing Agreement”), by and among Abbott, Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC, for themselves and as representatives of the several other underwriters named therein.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1800/000110465926025240/0001104659-26-025240-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Morgan Stanley & Co. LLC, Barclays Capital Inc., BofA Securities, Inc. and J.P. Morgan Securities LLC"},{"label":"Value","value":"$20,000,000,000 aggregate principal amount"},{"label":"Effective","value":"2026-02-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}